Literature DB >> 22256862

Combinatorial therapies to overcome B-RAF inhibitor resistance in melanomas.

Roger S Lo.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22256862      PMCID: PMC3383458          DOI: 10.2217/pgs.11.166

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


× No keyword cloud information.
  11 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV.

Authors:  Jarupon Fah Sathirapongsasuti; Hane Lee; Basil A J Horst; Georg Brunner; Alistair J Cochran; Scott Binder; John Quackenbush; Stanley F Nelson
Journal:  Bioinformatics       Date:  2011-08-09       Impact factor: 6.937

3.  Temporal dissection of tumorigenesis in primary cancers.

Authors:  Steffen Durinck; Christine Ho; Nicholas J Wang; Wilson Liao; Lakshmi R Jakkula; Eric A Collisson; Jennifer Pons; Sai-Wing Chan; Ernest T Lam; Catherine Chu; Kyunghee Park; Sung-woo Hong; Joe S Hur; Nam Huh; Isaac M Neuhaus; Siegrid S Yu; Roy C Grekin; Theodora M Mauro; James E Cleaver; Pui-Yan Kwok; Philip E LeBoit; Gad Getz; Kristian Cibulskis; Jon C Aster; Haiyan Huang; Elizabeth Purdom; Jian Li; Lars Bolund; Sarah T Arron; Joe W Gray; Paul T Spellman; Raymond J Cho
Journal:  Cancer Discov       Date:  2011-06-29       Impact factor: 39.397

4.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

5.  Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.

Authors:  Hubing Shi; Xiangju Kong; Antoni Ribas; Roger S Lo
Journal:  Cancer Res       Date:  2011-08-01       Impact factor: 12.701

6.  Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

Authors:  Jessie Villanueva; Adina Vultur; John T Lee; Rajasekharan Somasundaram; Mizuho Fukunaga-Kalabis; Angela K Cipolla; Bradley Wubbenhorst; Xiaowei Xu; Phyllis A Gimotty; Damien Kee; Ademi E Santiago-Walker; Richard Letrero; Kurt D'Andrea; Anitha Pushparajan; James E Hayden; Kimberly Dahlman Brown; Sylvie Laquerre; Grant A McArthur; Jeffrey A Sosman; Katherine L Nathanson; Meenhard Herlyn
Journal:  Cancer Cell       Date:  2010-12-14       Impact factor: 31.743

7.  Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.

Authors:  Ramin Nazarian; Hubing Shi; Qi Wang; Xiangju Kong; Richard C Koya; Hane Lee; Zugen Chen; Mi-Kyung Lee; Narsis Attar; Hooman Sazegar; Thinle Chodon; Stanley F Nelson; Grant McArthur; Jeffrey A Sosman; Antoni Ribas; Roger S Lo
Journal:  Nature       Date:  2010-11-24       Impact factor: 49.962

8.  Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

Authors:  Lecia V Sequist; Belinda A Waltman; Dora Dias-Santagata; Subba Digumarthy; Alexa B Turke; Panos Fidias; Kristin Bergethon; Alice T Shaw; Scott Gettinger; Arjola K Cosper; Sara Akhavanfard; Rebecca S Heist; Jennifer Temel; James G Christensen; John C Wain; Thomas J Lynch; Kathy Vernovsky; Eugene J Mark; Michael Lanuti; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Sci Transl Med       Date:  2011-03-23       Impact factor: 17.956

9.  A comprehensive catalogue of somatic mutations from a human cancer genome.

Authors:  Erin D Pleasance; R Keira Cheetham; Philip J Stephens; David J McBride; Sean J Humphray; Chris D Greenman; Ignacio Varela; Meng-Lay Lin; Gonzalo R Ordóñez; Graham R Bignell; Kai Ye; Julie Alipaz; Markus J Bauer; David Beare; Adam Butler; Richard J Carter; Lina Chen; Anthony J Cox; Sarah Edkins; Paula I Kokko-Gonzales; Niall A Gormley; Russell J Grocock; Christian D Haudenschild; Matthew M Hims; Terena James; Mingming Jia; Zoya Kingsbury; Catherine Leroy; John Marshall; Andrew Menzies; Laura J Mudie; Zemin Ning; Tom Royce; Ole B Schulz-Trieglaff; Anastassia Spiridou; Lucy A Stebbings; Lukasz Szajkowski; Jon Teague; David Williamson; Lynda Chin; Mark T Ross; Peter J Campbell; David R Bentley; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2009-12-16       Impact factor: 49.962

10.  RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

Authors:  Fei Su; Amaya Viros; Carla Milagre; Kerstin Trunzer; Gideon Bollag; Olivia Spleiss; Jorge S Reis-Filho; Xiangju Kong; Richard C Koya; Keith T Flaherty; Paul B Chapman; Min Jung Kim; Robert Hayward; Matthew Martin; Hong Yang; Qiongqing Wang; Holly Hilton; Julie S Hang; Johannes Noe; Maryou Lambros; Felipe Geyer; Nathalie Dhomen; Ion Niculescu-Duvaz; Alfonso Zambon; Dan Niculescu-Duvaz; Natasha Preece; Lídia Robert; Nicholas J Otte; Stephen Mok; Damien Kee; Yan Ma; Chao Zhang; Gaston Habets; Elizabeth A Burton; Bernice Wong; Hoa Nguyen; Mark Kockx; Luc Andries; Brian Lestini; Keith B Nolop; Richard J Lee; Andrew K Joe; James L Troy; Rene Gonzalez; Thomas E Hutson; Igor Puzanov; Bartosz Chmielowski; Caroline J Springer; Grant A McArthur; Jeffrey A Sosman; Roger S Lo; Antoni Ribas; Richard Marais
Journal:  N Engl J Med       Date:  2012-01-19       Impact factor: 91.245

View more
  10 in total

1.  Receptor tyrosine kinases in cancer escape from BRAF inhibitors.

Authors:  Roger S Lo
Journal:  Cell Res       Date:  2012-05-08       Impact factor: 25.617

2.  KRAS mutant tumor subpopulations can subvert durable responses to personalized cancer treatments.

Authors:  Barbara L Parsons; Meagan B Myers
Journal:  Per Med       Date:  2013-03       Impact factor: 2.512

3.  The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma.

Authors:  Jack McCain
Journal:  P T       Date:  2013-02

4.  miR-579-3p controls melanoma progression and resistance to target therapy.

Authors:  Luigi Fattore; Rita Mancini; Mario Acunzo; Giulia Romano; Alessandro Laganà; Maria Elena Pisanu; Debora Malpicci; Gabriele Madonna; Domenico Mallardo; Marilena Capone; Franco Fulciniti; Luca Mazzucchelli; Gerardo Botti; Carlo M Croce; Paolo Antonio Ascierto; Gennaro Ciliberto
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-08       Impact factor: 11.205

5.  A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.

Authors:  Hubing Shi; Aayoung Hong; Xiangju Kong; Richard C Koya; Chunying Song; Gatien Moriceau; Willy Hugo; Clarissa C Yu; Charles Ng; Thinle Chodon; Richard A Scolyer; Richard F Kefford; Antoni Ribas; Georgina V Long; Roger S Lo
Journal:  Cancer Discov       Date:  2013-11-21       Impact factor: 39.397

6.  Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.

Authors:  Luigi Fattore; Debora Malpicci; Emanuele Marra; Francesca Belleudi; Alessia Noto; Claudia De Vitis; Maria Elena Pisanu; Pierpaolo Coluccia; Rosa Camerlingo; Giuseppe Roscilli; Antoni Ribas; Arianna Di Napoli; Maria Rosaria Torrisi; Luigi Aurisicchio; Paolo Antonio Ascierto; Rita Mancini; Gennaro Ciliberto
Journal:  Oncotarget       Date:  2015-09-22

Review 7.  MicroRNAs in melanoma development and resistance to target therapy.

Authors:  Luigi Fattore; Susan Costantini; Debora Malpicci; Ciro Francesco Ruggiero; Paolo Antonio Ascierto; Carlo M Croce; Rita Mancini; Gennaro Ciliberto
Journal:  Oncotarget       Date:  2017-03-28

8.  Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies.

Authors:  Luigi Fattore; Emanuele Marra; Maria Elena Pisanu; Alessia Noto; Claudia de Vitis; Francesca Belleudi; Luigi Aurisicchio; Rita Mancini; Maria Rosaria Torrisi; Paolo Antonio Ascierto; Gennaro Ciliberto
Journal:  J Transl Med       Date:  2013-07-27       Impact factor: 5.531

Review 9.  Emerging targeted therapies for melanoma treatment (review).

Authors:  Angela Russo; Bartolomea Ficili; Saverio Candido; Franca Maria Pezzino; Claudio Guarneri; Antonio Biondi; Salvatore Travali; James A McCubrey; Demetrios A Spandidos; Massimo Libra
Journal:  Int J Oncol       Date:  2014-06-03       Impact factor: 5.650

10.  miR- 26a Sensitizes Melanoma Cells To Dabrafenib Via Targeting HMGB1-Dependent Autophagy Pathways.

Authors:  Yan Yu; Niu Xiang; Min Lin; Jin-Wen Huang; Jing Zhang; Bo Cheng; Chao Ji
Journal:  Drug Des Devel Ther       Date:  2019-10-29       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.